AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
E
Eton Pharmaceuticals, Inc.ETON · Nasdaq
1 asset: 1 Ph 3Diazepam (Libervant)Phase 3 · EpilepsyWeak signalNone on record$1.8B$56MSep 2026Cash-flow positive$9.9M
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK · Nasdaq
2 assets: 1 Ph 3, 1 otherZorevunersenPhase 3 · Dravet SyndromeWeak signalMar 2027Zorevunersen · Phase 3$1.7B$319MSep 2026~6.1 qtrs$191M
Maze Therapeutics logo
Maze TherapeuticsMAZE · Nasdaq
1 asset: 1 Ph 2MZE829Phase 2 · Chronic Kidney DiseaseNone on record$1.7B$391MSep 2026~13.6 qtrs$137M
Vir Biotechnology logo
Vir BiotechnologyVIR · Nasdaq
1 asset: 1 Ph 3Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis DeltaDec 2026Tobevibart (VIR-3434) · Phase 3$1.6B$463MSep 2026~13.1 qtrs$413M
Sarepta Therapeutics logo
Sarepta TherapeuticsSRPT · Nasdaq
3 assets: 2 Ph 2, 1 Ph 1SRP-1001Phase 1/2 · Facioscapulohumeral Muscular Dystrophy31 Dec 2026SRP-1003 · Phase 1/2$1.6B$879MSep 2026Cash-flow positive$653M
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX ·
2 assets: 1 Ph 3, 1 Ph 1bexobrutidegPhase 3 · Chronic Lymphocytic LeukemiaJan 2027bexobrutideg · Phase 1$1.5B$1.0BAug 2026Cash-flow positive$334M
Precigen, Inc logo
Precigen, IncPGEN ·
3 assets: 1 approved, 1 Ph 2, 1 Ph 1PRGN-2009Phase 2 · HPV-Associated Oropharyngeal CancerWeak signal2 Dec 2027Zopapogene imadenovec · Approved$1.5B$46MSep 2026~2.5 qtrs~$30M
Kailera Therapeutics logo
Kailera TherapeuticsKLRA · Nasdaq
3 assets: 2 Ph 3, 1 Ph 2ribupatidePhase 3 · ObesityReliable signalDec 2026Safiglipron (HRS-7535) · Phase 2$1.5B$901MSep 2026~11.7 qtrs~$284M
Mesoblast logo
MesoblastMESO · Nasdaq
2 assets: 1 approved, 1 Ph 3rexlemestrocel-LPhase 3 · Heart FailurePartial signalJul 2027rexlemestrocel-L · Phase 3$1.5B$122MMar 2026~29.8 qtrs$35M
P
Pacira BioSciences, Inc.PCRX · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$1.5B$296MSep 2026Cash-flow positive$123M
AnaptysBio logo
AnaptysBioANAB · Nasdaq
1 asset: 1 Ph 3ImsidolimabPhase 3 · PsoriasisPartial signalNone on record$1.4B$153MSep 2026Cash-flow positive$122M
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP · Nasdaq
1 asset: 1 Ph 3RAP-219Phase 3 · EpilepsyWeak signalJun 2027RAP-219 · Phase 1$1.4B$395MSep 2026~13.1 qtrs$149M
Nuvation Bio logo
Nuvation BioNUVB · NYSE
2 assets: 1 approved, 1 Ph 3safusidenibPhase 3 · Glioma2 Feb 2027Taletrectinib · Phase 1$1.3B$663MSep 2026~25.0 qtrs$133M
MannKind Corporation logo
MannKind CorporationMNKD · Nasdaq
3 assets: 3 approvedApproved assets onlyMar 2027Afrezza · Phase 2$1.3B$97MSep 2026~5.8 qtrs$77M
Innoviva logo
InnovivaINVA · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$1.3B$581MSep 2026Cash-flow positive$20M
OCULAR THERAPEUTIX, INC logo
OCULAR THERAPEUTIX, INCOCUL · Nasdaq
2 assets: 1 approved, 1 Ph 3Axitinib intravitreal implant (OTX-TKI)Phase 3 · Age-Related Macular DegenerationPartial signal8 Jan 2027Axitinib intravitreal implant (OTX-TKI) · Phase 3$1.3B$532MSep 2026~8.4 qtrs$246M
uniQure logo
uniQureQURE · Nasdaq
3 assets: 1 approved, 2 Ph 2AMT-260Phase 1/2 · Epilepsy30 Nov 2026AMT-260 · Phase 1/2$1.3B$670MSep 2026~13.9 qtrs$133M
OPKO Health logo
OPKO HealthOPK · Nasdaq
3 assets: 2 approved, 1 Ph 2OPK-88006Phase 1/2 · MASH / NASHOct 2027Extended-release calcifediol · Phase 2$1.3B$403MSep 2026~12.9 qtrs$127M
Alto Neuroscience logo
Alto NeuroscienceANRO · NYSE
6 assets: 6 Ph 2ALTO-100Phase 2 · Major Depressive DisorderPartial signalDec 2026ALTO-300 · Phase 2$1.2B$320MSep 2026~16.2 qtrs$73M
Avalyn Pharma Inc. logo
Avalyn Pharma Inc.AVLN · Nasdaq
1 asset: 1 Ph 2Pirfenidone (AP01)Phase 2Jun 2027Pirfenidone (AP01) · Phase 2$1.2B$327MSep 2026~13.2 qtrs~$95M
Harrow, Inc. logo
Harrow, Inc.HROW · Nasdaq
4 assets: 4 approvedApproved assets onlyNone on record$1.2B$75MSep 2026~15.9 qtrs$36M
Savara Inc. logo
Savara Inc.SVRA · Nasdaq
1 asset: 1 Ph 3molgramostimPhase 3 · Autoimmune Pulmonary Alveolar ProteinosisReliable signalJun 2027molgramostim · Phase 3$1.2B$130MSep 2026~4.0 qtrs$91M
Nektar Therapeutics logo
Nektar TherapeuticsNKTR · Nasdaq
2 assets: 1 Ph 3, 1 otherrezpegaldesleukinPhase 3 · Atopic DermatitisPartial signalMay 2028rezpegaldesleukin · Phase 3$1.2B$614MSep 2026~9.6 qtrs$149M
Kardigan logo
KardiganKARD · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2DanicamtivPhase 3 · Heart FailureWeak signalDec 2026Tonlamarsen · Phase 2$1.2B$472MSep 2026~8.9 qtrs$189M
LB Pharmaceuticals logo
LB PharmaceuticalsLBRX · Nasdaq
1 asset: 1 Ph 3LB-102 (methylated amisulpride)Phase 3 · SchizophreniaReliable signalNone on record$1.1B$404MSep 2026~11.3 qtrs$119M
Mineralys Therapeutics logo
Mineralys TherapeuticsMLYS · Nasdaq
1 asset: 1 Ph 3LorundrostatPhase 3 · HypertensionReliable signalNone on record$1.1B$625MSep 2026~16.3 qtrs$293M
GH Research logo
GH ResearchGHRS · Nasdaq
1 asset: 1 Ph 2Mebufotenin (5-MeO-DMT)Phase 2 · Major Depressive DisorderPartial signalNone on record$1.1B$246MDec 2025~22.6 qtrs$39M
COMPASS Pathways logo
COMPASS PathwaysCMPS · Nasdaq
1 asset: 1 Ph 3Psilocybin (COMP360)Phase 3 · Major Depressive DisorderReliable signalNov 2028Psilocybin (COMP360) · Phase 2/3$1.1B$444MSep 2026~10.1 qtrs$109M
Jade Biosciences, Inc. logo
Jade Biosciences, Inc.JBIO · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1JADE101Phase 3 · IgA NephropathyMay 2027JADE101 · Phase 1$1.1B$476MSep 2026~14.6 qtrs$145M
Vor Bio logo
Vor BioVOR · Nasdaq
1 asset: 1 Ph 3TelitaciceptPhase 3 · Rheumatoid ArthritisReliable signal31 Dec 2026Telitacicept · Phase 3$1.1B$482MSep 2026~16.2 qtrs$97M
Omeros Corporation logo
Omeros CorporationOMER · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$1.1B$132MJun 2026~7.7 qtrs$63M
Inhibrx Biosciences, Inc logo
Inhibrx Biosciences, IncINBX ·
2 assets: 1 Ph 3, 1 Ph 2OrdastobartPhase 2/3 · Head and Neck Squamous Cell Carcinoma28 Feb 2027Ordastobart · Phase 2$1.0B$199MSep 2026~6.0 qtrs$100M
Seaport Therapeutics logo
Seaport TherapeuticsSPTX · Nasdaq
1 asset: 1 Ph 2GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive DisorderMar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2$980M$290MSep 2026~13.7 qtrs~$90M
Monte Rosa Therapeutics, Inc logo
Monte Rosa Therapeutics, IncGLUE ·
2 assets: 2 Ph 2MRT-2359Phase 2 · Prostate CancerDec 2026MRT-2359 · Phase 1/2$924M$583MSep 2026~14.1 qtrs$179M
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX · Nasdaq
1 asset: 1 Ph 3sonelokimabPhase 3 · Psoriatic ArthritisReliable signal4 Jan 2027sonelokimab · Phase 3$875M$501MSep 2026~8.2 qtrs$230M
Verastem, Inc. logo
Verastem, Inc.VSTM · Nasdaq
2 assets: 1 approved, 1 Ph 3GFH375Phase 3 · Non-Small Cell Lung Cancer30 Apr 2027GFH375 · Phase 2$866M$173MSep 2026~12.3 qtrswith a later raise$180M
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS · Nasdaq
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1soquelitinibPhase 3 · Peripheral T-Cell LymphomaWeak signal30 Dec 2026soquelitinib · Phase 1$860M$203MSep 2026~18.0 qtrs$55M
Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022) logo
Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022)COLL · Nasdaq
3 assets: 3 approvedApproved assets onlyNone on record$806M$166MSep 2026Cash-flow positive$7.0M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL ·
5 assets: 4 approved, 1 Ph 2R289Phase 1/2 · Myelodysplastic Syndromes4 Dec 2026Vepdegestrant · Phase 1$801M$99MSep 2026Cash-flow positive$28M
ORIC Pharmaceuticals logo
ORIC PharmaceuticalsORIC · Nasdaq
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1RinzimetostatPhase 3 · Prostate CancerDec 2026Enozertinib · Phase 1$793M$265MJun 2026~9.5 qtrs$122M
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD · Nasdaq
2 assets: 1 approved, 1 Ph 3apraglutidePhase 3 · Short Bowel SyndromeNone on record$791M$86MSep 2026Cash-flow positive$95M
Ardelyx logo
ArdelyxARDX · Nasdaq
2 assets: 2 approvedApproved assets only26 Feb 2027Tenapanor (Ibsrela) · Phase 3$784M$285MSep 202610+ years$94M
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX · Nasdaq
2 assets: 1 approved, 1 Ph 2PilavapadinPhase 2 · Diabetic Peripheral Neuropathic PainPartial signalJan 2027Sotagliflozin (Inpefa) · Phase 3$766M$183MSep 2026~14.9 qtrs$58M
Syndax logo
SyndaxSNDX ·
2 assets: 2 approvedApproved assets only6 Jan 2027Axatilimab · Phase 1/2$764M$427MSep 2026~9.6 qtrs$273M
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM · Nasdaq
1 asset: 1 Ph 2budoprutugPhase 2 · Primary Membranous NephropathyApr 2027budoprutug · Phase 1$756M$206MSep 2026~15.6 qtrs$44M
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA ·
2 assets: 1 Ph 3, 1 Ph 1PalazestrantPhase 3 · HR+/HER2- Metastatic Breast CancerWeak signal30 May 2027OP-3136 · Phase 1$714M$414MSep 2026~9.3 qtrs$218M
Attovia Therapeutics logo
Attovia TherapeuticsATTO · Nasdaq
1 asset: 1 Ph 1ATTO-1310Phase 1 · Atopic Dermatitis30 Aug 2028ATTO-1310 · Phase 2$709M$396MSep 2026~19.4 qtrs~$65M
Nuvectis Pharma logo
Nuvectis PharmaNVCT · Nasdaq
1 asset: 1 Ph 1NXP900Phase 1 · Non-Small Cell Lung CancerDec 2026NXP900 · Phase 1$698M$141MSep 2026~36.0 qtrs$41M
Kura Oncology, Inc. logo
Kura Oncology, Inc.KURA · Nasdaq
2 assets: 1 approved, 1 Ph 1DarlifarnibPhase 1 · Non-Small Cell Lung CancerDec 2026Ziftomenib · Phase 1$674M$492MSep 2026~11.6 qtrs$258M
Annexon, Inc. logo
Annexon, Inc.ANNX · Nasdaq
3 assets: 2 Ph 3, 1 Ph 1VonaprumentPhase 3 · Age-Related Macular DegenerationPartial signal31 May 2027tanruprubart · Phase 3$667M$214MSep 2026~4.5 qtrs$166M
Inventiva logo
InventivaIVA · Nasdaq
1 asset: 1 Ph 3LanifibranorPhase 3 · MASH / NASHPartial signalNone on record$655M$100MDec 2024~9.1 qtrswith a later raise$98M
Geron Corporation logo
Geron CorporationGERN · Nasdaq
1 asset: 1 approvedApproved assets onlyFeb 2027Imetelstat · Phase 1$638M$286MSep 2026~12.7 qtrs$63M
Janux Therapeutics logo
Janux TherapeuticsJANX · Nasdaq
1 asset: 1 Ph 1JANX007Phase 1 · Prostate CancerJul 2027JANX007 · Phase 1$631M$946MSep 202610+ years$120M
Cullinan Therapeutics Inc. logo
Cullinan Therapeutics Inc.CGEM ·
4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1Velinotamig (GR1803)Phase 3 · Multiple MyelomaWeak signalDec 2026CLN-978 · Phase 1$585M$290MSep 2026~7.0 qtrs$170M
Alumis logo
AlumisALMS · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1EnvudeucitinibPhase 3 · PsoriasisReliable signal1 Dec 2027Envudeucitinib · Phase 2$560M$433MSep 2026~5.4 qtrs$330M
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS · Nasdaq
4 assets: 3 Ph 2, 1 otherBosakitugPhase 2 · Atopic DermatitisWeak signalMar 2029Modzatinib · Phase 2$555M$114MSep 2026~6.5 qtrs$66M
Wave Life Sciences logo
Wave Life SciencesWVE · Nasdaq
4 assets: 4 Ph 2WVE-003Phase 1/2 · Huntington's DiseaseWeak signalSep 2027WVE-006 · Phase 1/2$546M$431MSep 2026~8.3 qtrs$205M
A
ArriVent BioPharmaAVBP · Nasdaq
1 asset: 1 Ph 3FurmonertinibPhase 3 · Non-Small Cell Lung CancerDec 2026Furmonertinib · Phase 3$537M$393MSep 2026~10.3 qtrs$151M
Gyre Therapeutics logo
Gyre TherapeuticsGYRE · Nasdaq
1 asset: 1 otherF230Pulmonary Arterial HypertensionNone on record$500M$57MSep 2026~9.9 qtrs$17M
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST · Nasdaq
3 assets: 1 approved, 1 Ph 3, 1 otherDiazepam (Libervant)Phase 3 · EpilepsyWeak signalNone on record$475M$90MSep 2026~9.1 qtrs$16M
Capricor Therapeutics logo
Capricor TherapeuticsCAPR · Nasdaq
1 asset: 1 Ph 3deramiocelPhase 3 · Duchenne Muscular DystrophyNone on record$467M$199MSep 2026~6.6 qtrs$109M
BlossomHill Therapeutics logo
BlossomHill TherapeuticsBLSM ·
2 assets: 1 Ph 2, 1 Ph 1BH-30643Phase 1/2 · Non-Small Cell Lung Cancer31 Jan 2029BH-30643 · Phase 1/2$464M$225MSep 2026~13.3 qtrs~$70M
DiaMedica Therapeutics logo
DiaMedica TherapeuticsDMAC · Nasdaq
1 asset: 1 Ph 3Rinvecalinase alfaPhase 2/3 · Acute Ischemic StrokeDec 2026Rinvecalinase alfa · Phase 2/3$463M$35MSep 2026~4.1 qtrs$32M
Assembly Biosciences logo
Assembly BiosciencesASMB · Nasdaq
1 asset: 1 Ph 1ABI-5366Phase 1 · Genital HerpesNone on record$458M$314MSep 2026~31.0 qtrs$67M
Arvinas Inc. logo
Arvinas Inc.ARVN ·
4 assets: 1 approved, 2 Ph 2, 1 Ph 1LuxdegalutamidePhase 2 · Metastatic Castration-Resistant Prostate Cancer3 Dec 2026Luxdegalutamide · Phase 2$443M$559MSep 2026~14.1 qtrs$221M
C
Cypherpunk Technologies Inc.CYPH · Nasdaq
1 asset: 1 Ph 2SirexatamabPhase 2 · Colorectal CancerNone on record$440M$7.6MJun 2026Ended Nov 2026$2.6M
Helus Pharma logo
Helus PharmaHELP · Nasdaq
1 asset: 1 Ph 3DeupsilocinPhase 3 · Major Depressive DisorderPartial signalNone on record$427M——$39M
Tectonic Therapeutic logo
Tectonic TherapeuticTECX · Nasdaq
1 asset: 1 Ph 2Fc-relaxin fusion protein (TX45)Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease24 Nov 2026Fc-relaxin fusion protein (TX45) · Phase 2$420M$235MSep 2026~13.6 qtrs$73M
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL · Nasdaq
1 asset: 1 Ph 3Aglatimagene BesadenovecPhase 3 · Non-Small Cell Lung CancerFeb 2027Aglatimagene Besadenovec · Phase 2$417M$204MSep 2026~11.8 qtrs$56M
Avalo Therapeutics, Inc. logo
Avalo Therapeutics, Inc.AVTX · Nasdaq
2 assets: 2 Ph 2QuisovalimabPhase 2 · AsthmaPartial signalNone on record$387M$393MSep 2026~24.8 qtrs$66M
Jasper Therapeutics, Inc. logo
Jasper Therapeutics, Inc.JSPR · Nasdaq
1 asset: 1 Ph 2BriquilimabPhase 1/2 · Chronic Spontaneous UrticariaPartial signalNone on record$383M$7.7MJun 2026Ended Aug 2026$37M
Opus Genetics, Inc. logo
Opus Genetics, Inc.IRD · Nasdaq
1 asset: 1 Ph 3OPGx-LCA5Phase 3 · Leber Congenital Amaurosis15 Jun 2028OPGx-LCA5 · Phase 1/2$379M$89MSep 2026~7.3 qtrs$47M
Puma Biotechnology logo
Puma BiotechnologyPBYI · Nasdaq
2 assets: 1 approved, 1 Ph 2AlisertibPhase 2 · Small Cell Lung Cancer30 Oct 2027Alisertib · Phase 2$373M$109MSep 2026Cash-flow positive$74M
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY · Nasdaq
1 asset: 1 approvedApproved assets onlyApr 2027Epinephrine · Approved$367M$138MSep 2026~3.0 qtrs$31M
CorMedix logo
CorMedixCRMD · Nasdaq
1 asset: 1 approvedApproved assets onlyJan 2028Taurolidine/heparin · Phase 3$351M$356MSep 2026Cash-flow positive$30M
Adlai Nortye Biopharma Co., Ltd. logo
Adlai Nortye Biopharma Co., Ltd.ANL · Nasdaq
1 asset: 1 Ph 2PalupiprantPhase 2 · Non-Small Cell Lung CancerWeak signalNone on record$350M$61MDec 2024Ended Mar 2026$45M
Lyell Immunopharma, Inc. logo
Lyell Immunopharma, Inc.LYEL · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2Rondecabtagene autoleucelPhase 3 · Large B-Cell LymphomaJun 2028LYL273 · Phase 1/2$341M$179MSep 2026~5.1 qtrs$170M
Prelude Therapeutics logo
Prelude TherapeuticsPRLD · Nasdaq
1 asset: 1 Ph 2PRT3789Phase 2 · Non-Small Cell Lung CancerWeak signalNone on record$340M$152MJun 2026~6.1 qtrs$108M
Immunic, Inc. logo
Immunic, Inc.IMUX · Nasdaq
2 assets: 1 Ph 3, 1 othervidofludimus calciumPhase 3 · Multiple SclerosisNov 2026vidofludimus calcium · Phase 3$328M$132MSep 2026~5.5 qtrs$95M
ProKidney logo
ProKidneyPROK · Nasdaq
1 asset: 1 Ph 3RilparencelPhase 3 · Chronic Kidney DiseaseWeak signalDec 2029Rilparencel · Phase 3$314M$81MSep 2026~2.1 qtrs$145M
MapLight Therapeutics logo
MapLight TherapeuticsMPLT · Nasdaq
1 asset: 1 Ph 2Betovumeline/fesoterodine (ML-007C-MA)Phase 2 · Alzheimer's DiseasePartial signalDec 2027Betovumeline/fesoterodine (ML-007C-MA) · Phase 2$309M$305MJun 2026~7.0 qtrs$199M
Galectin Therapeutics Inc. logo
Galectin Therapeutics Inc.GALT · Nasdaq
1 asset: 1 Ph 3belapectinPhase 2/3 · MASH / NASHPartial signalNone on record$301M$13MJun 2026~2.7 qtrs$8.9M
Whitehawk Therapeutics, Inc. logo
Whitehawk Therapeutics, Inc.WHWK ·
1 asset: 1 Ph 1HWK-007Phase 1 · Non-Small Cell Lung CancerOct 2028HWK-007 · Phase 1$294M$170MSep 2026~9.2 qtrs$67M
Agenus Inc. logo
Agenus Inc.AGEN ·
2 assets: 1 Ph 3, 1 Ph 2BotensilimabPhase 3 · Colorectal CancerSep 2027Balstilimab · Phase 2$290M$87MSep 2026~3.3 qtrs$46M
Evommune logo
EvommuneEVMN · NYSE
3 assets: 3 Ph 2EVO101Phase 2 · Atopic DermatitisPartial signalOct 2027EVO756 · Phase 2$284M$170MSep 2026~7.5 qtrs$89M
Emergent BioSolutions logo
Emergent BioSolutionsEBS · NYSE
3 assets: 3 approvedApproved assets onlyNone on record$283M$177MSep 2026Cash-flow positive$41M
Autolus Therapeutics plc logo
Autolus Therapeutics plcAUTL · Nasdaq
1 asset: 1 approvedApproved assets onlySep 2027obecabtagene autoleucel · Phase 1$282M$250MSep 2026~5.7 qtrs$116M
Eikon Therapeutics logo
Eikon TherapeuticsEIKN · Nasdaq
1 asset: 1 Ph 3ResiquimodPhase 2/3 · Non-Small Cell Lung CancerDec 2026Resiquimod · Phase 2$280M$462MSep 2026~8.2 qtrs$269M
Inhibikase Therapeutics logo
Inhibikase TherapeuticsIKT · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2Imatinib mesylate prodrug (IkT-001Pro)Phase 3 · Pulmonary Arterial HypertensionJun 2029Imatinib mesylate prodrug (IkT-001Pro) · Phase 3$277M$193MSep 2026~15.7 qtrs$46M
C4 Therapeutics, Inc. logo
C4 Therapeutics, Inc.CCCC · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1CemsidomidePhase 2 · Multiple MyelomaJun 2027CFT8919 · Phase 1$274M$209MSep 2026~10.5 qtrs$99M
Altimmune logo
AltimmuneALT · Nasdaq
1 asset: 1 Ph 3pemvidutidePhase 3 · MASH / NASHReliable signal30 Sep 2027pemvidutide · Phase 2$270M$265MSep 2026~10.4 qtrs$80M
Q32 Bio logo
Q32 BioQTTB · Nasdaq
1 asset: 1 Ph 2BempikibartPhase 2 · Atopic DermatitisPartial signalNone on record$255M$290MSep 202610+ years$16M
Protalix BioTherapeutics, Inc. logo
Protalix BioTherapeutics, Inc.PLX · NYSE American
2 assets: 1 approved, 1 Ph 2PRX-115Phase 2 · Severe Refractory GoutOct 2027pegunigalsidase alfa · Phase 2/3$255M$22MSep 2026Cash-flow positive$22M
Allogene Therapeutics, Inc. logo
Allogene Therapeutics, Inc.ALLO · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1cemacabtagene ansegedleucelPhase 2 · Large B-Cell LymphomaDec 2027cemacabtagene ansegedleucel · Phase 2$240M$303MSep 2026~11.2 qtrs$133M
Amarin Corporation logo
Amarin CorporationAMRN · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$236M$323MSep 2026Cash-flow positive$19M
Lexeo Therapeutics logo
Lexeo TherapeuticsLXEO · Nasdaq
1 asset: 1 Ph 2LX1001Phase 1/2 · Alzheimer's DiseaseWeak signalNov 2028LX1001 · Phase 1$232M$215MJun 2026~9.7 qtrs$67M
Vanda Pharmaceuticals logo
Vanda PharmaceuticalsVNDA · Nasdaq
6 assets: 4 approved, 2 Ph 3ImsidolimabPhase 3 · PsoriasisPartial signal1 Dec 2026tradipitant · Phase 3$227M$141MSep 2026~4.6 qtrs$122M
Faeth Therapeutics, Inc. logo
Faeth Therapeutics, Inc.FTH · Nasdaq
4 assets: 3 Ph 2, 1 otherSerabelisibPhase 2 · Endometrial CancerWeak signalSep 2028Serabelisib · Phase 2$225M$175MSep 2026~16.2 qtrs—
AC Immune logo
AC ImmuneACIU · Nasdaq
3 assets: 3 Ph 2ACI-35.030Phase 2 · Alzheimer's DiseasePartial signal22 Dec 2026ACI-35.030 · Phase 2$214M$115MDec 2025~5.5 qtrs$68M
Palisade Bio logo
Palisade BioPALI · Nasdaq
1 asset: 1 Ph 2PALI-2108Phase 2 · Ulcerative ColitisWeak signalOct 2027PALI-2108 · Phase 2$205M$114MSep 2026~18.3 qtrs$31M

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415